SCHEMBL6030700

SCHEMBL6030700

CC1CCCCC1C(=O)Nc1ccc(-c2ncc(-c3ccc(NC(=O)C4CCCCCC4)cc3)[nH]2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.51
PTPN2 P17706 1/20 0.51
RAB9A P51151 3/20 0.44
NPC1 O15118 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
SCN3A Q9NY46 2/20 0.44
SCN9A Q15858 1/20 0.44
HPGD P15428 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
ENPP3 O14638 1/20 0.41
ENPP1 P22413 1/20 0.41
TP53 P04637 1/20 0.41
LMNA P02545 1/20 0.40
KIT P10721 1/20 0.40
KDR P35968 1/20 0.40
FLT3 P36888 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6888068 1.00 PTPN1 (0.51) PTPN1PTPN2RAB9ANPC1SMN1; SMN2
SCHEMBL6029811 1.00 PTPN1 (0.51) PTPN1PTPN2RAB9ANPC1SMN1; SMN2
SCHEMBL6031823 1.00 PTPN1 (0.51) PTPN1PTPN2RAB9ANPC1SMN1; SMN2
SCHEMBL6887689 0.94 PTPN1 (0.44) PTPN1PTPN2RAB9ANPC1SMN1; SMN2
SCHEMBL6028790 0.90 PTPN1 (0.62) PTPN1PTPN2RAB9ANPC1SMN1; SMN2
SCHEMBL14305032 0.90 PTPN1 (0.62) PTPN1PTPN2RAB9ANPC1SMN1; SMN2
SCHEMBL14311202 0.90 PTPN1 (0.62) PTPN1PTPN2RAB9ANPC1SMN1; SMN2
SCHEMBL6028360 0.90 PTPN1 (0.62) PTPN1PTPN2RAB9ANPC1SMN1; SMN2
SCHEMBL6028319 0.88 PTPN1 (0.54) PTPN1PTPN2RAB9ANPC1SMN1; SMN2
SCHEMBL6029160 0.88 PTPN1 (0.54) PTPN1PTPN2RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1826111-A Imidazole derivatives for treatment of allergic and hyperproliferative disorders AVANIR PHARMACEUTICALS (US) 2006-08-30 CN disclosed
EP-1613310-A1 IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS Avanir Pharmaceuticals (US) 2006-01-11 EP disclosed
US-20040229927-A1 Imidazole derivatives for treatment of allergic and hyperproliferative disorders AVANIR PHARMACEUTICALS 2004-11-18 US disclosed
WO-2004091610-A1 IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS AVANIR PHARMACEUTICALS (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229927-A1 Imidazole derivatives for treatment of allergic and hyperproliferative disorders ICOS, TSLP, IKZF3 PTPN1 2513/4885PTPN2 2100/4885RAB9A 3864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.